BridgeBio Pharma, Inc. Increase (Decrease) in Deferred Revenue
BridgeBio Pharma, Inc. (BBIO) reported Increase (Decrease) in Deferred Revenue of -$4.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-08-10
- BridgeBio Pharma, Inc. increase (decrease) in deferred revenue for the quarter ending 2026-06-30 was -$1.92M.
- BridgeBio Pharma, Inc. increase (decrease) in deferred revenue for the quarter ending 2026-03-31 was -$2.38M.
- BridgeBio Pharma, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-12-31 was -$1.95M, a 249.85% decline year-over-year.
- BridgeBio Pharma, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-09-30 was -$2.99M.
- BridgeBio Pharma, Inc. increase (decrease) in deferred revenue for fiscal 2025 was -$11.43M, a 152.24% decline from fiscal 2024.
- BridgeBio Pharma, Inc. increase (decrease) in deferred revenue for fiscal 2024 was $21.88M.
- BridgeBio Pharma, Inc. increase (decrease) in deferred revenue for fiscal 2023 was -$5.44M, a 135.63% decline from fiscal 2022.
- BridgeBio Pharma, Inc. increase (decrease) in deferred revenue for fiscal 2022 was $15.26M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$4.30M 10-Q · filed 2026-08-10 | -$6.25M derived: sum of 3 quarters · filed 2026-08-10 | -$9.24M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$2.38M 10-Q · filed 2026-05-07 | -$4.33M derived: sum of 2 quarters · filed 2026-05-07 | -$7.32M derived: sum of 3 quarters · filed 2026-05-07 | -$11.24M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$1.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$4.94M derived: sum of 2 quarters · filed 2026-02-24 | -$8.86M derived: sum of 3 quarters · filed 2026-08-10 | -$11.43M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$2.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | -$6.91M derived: sum of 2 quarters · filed 2026-08-10 | -$9.48M 10-Q · filed 2025-10-29 | -$8.18M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$3.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$6.49M 10-Q · filed 2026-08-10 | -$5.19M derived: sum of 3 quarters · filed 2026-08-10 | -$6.85M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$2.57M 10-Q · filed 2026-05-07 | -$1.27M derived: sum of 2 quarters · filed 2026-05-07 | -$2.93M derived: sum of 3 quarters · filed 2026-05-07 | -$4.72M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$361.00K derived: sum of 2 quarters · filed 2026-02-24 | -$2.15M derived: sum of 3 quarters · filed 2026-02-24 | $21.88M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$1.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | -$3.45M derived: sum of 2 quarters · filed 2025-10-29 | $20.57M 10-Q · filed 2025-10-29 | $19.60M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$1.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $22.24M 10-Q · filed 2025-08-05 | $21.26M derived: sum of 3 quarters · filed 2026-02-24 | $19.98M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $24.02M 10-Q · filed 2025-04-29 | $23.05M derived: sum of 2 quarters · filed 2026-02-24 | $21.77M derived: sum of 3 quarters · filed 2026-02-24 | $20.33M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | -$974.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$2.25M derived: sum of 2 quarters · filed 2026-02-24 | -$3.69M derived: sum of 3 quarters · filed 2026-02-24 | -$5.44M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$1.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$2.72M derived: sum of 2 quarters · filed 2024-11-12 | -$4.46M 10-Q · filed 2024-11-12 | -$6.17M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | -$1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$3.18M 10-Q · filed 2024-08-01 | -$4.89M derived: sum of 3 quarters · filed 2025-02-20 | -$4.56M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | -$1.75M 10-Q · filed 2024-05-02 | -$3.46M derived: sum of 2 quarters · filed 2025-02-20 | -$3.13M derived: sum of 3 quarters · filed 2025-02-20 | $13.51M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | -$1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | -$1.38M derived: sum of 2 quarters · filed 2025-02-20 | $15.26M derived: sum of 3 quarters · filed 2025-02-20 | $15.26M 10-K · filed 2025-02-20 |
| 2022-09-30 | $328.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $16.97M derived: sum of 2 quarters · filed 2023-11-02 | $16.97M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $16.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $16.64M 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-22 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |